PROS1 and prostate carcinoma: It is suggested to refer patients with a progressive increase in PSA during testosterone replacement therapy or with absolute PSA values > 4.0 ng/mL or >3 ng/mL in presence of a high risk prostatic carcinoma (a first-degree relative with prostatic carcinoma) to the urologist.